Antibody-drug conjugates (ADCs) are high-potent active pharmaceutical ingredients that compromise chemotherapy agents coupled to tumor-target antibodies. However, ADCs are extremely toxic in concentrated forms present in manufacturing and analytical settings.
The team aims to make surrogate ADCs "sADCs", that will have similar chemical size and structure without the extreme toxicity.
Completed the design, chemical synthesis and characterization of two different fluorheads with associated linking chemistries, “SMCC-AS20” and “Mal-PEG12-PS19” that are good mimics for auristatin- and pyrrolobenzodiazepine-based warhead-linker species, respectively, that are in current therapeutic use. These novel compounds are ready for conjugation to representative antibodies to produce sADCs.
sADCs will facilitate exploratory process research and development for work ADCs by manufacturers and vendors.
For the analytical chemistry/process analytical technology discipline, sADCs can serve as a convienent analytical reference/calibration standard for critical quality attribute asessment and facilitate the development of new analytical technologies.
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Rensselaer Polytechnic Institute
AstraZeneca
Carnegie Mellon University
EMD Millipore Corporation
